Latest Us Market News

OD6 Metals has recalibrated its Horseshoe fluorspar grades upward by nearly 13% following a re-assay program, confirming exceptional high-grade mineralisation near surface at its Quinn Project in Nevada.

Mader Group Limited has surpassed $1 billion in revenue for the first time, reporting a 15% increase in both revenue and net profit after tax for the financial year ended 30 June 2026. The company continues to expand its global footprint with strong growth in Australia and North America.

Andromeda Metals has successfully produced 4N High Purity Alumina (HPA) with 99.9986% purity at continuous pilot scale, marking a crucial step towards commercialisation and customer evaluation under a strategic supply agreement with Traxys.

Cyclopharm Limited posted a fifth consecutive record half-year revenue of $17.5 million, propelled by a 74% jump in US Technegas® sales and a doubling of revenue-generating US sites. New US clinical guidelines naming Technegas® as the preferred ventilation imaging agent underpin a robust growth outlook despite a wider net loss.

Reece Limited posted a 4.5% revenue increase to $9.38 billion in FY26, driven by a strong ANZ recovery and tempered by ongoing challenges in the US residential market. Despite flat EBITDA and a slight dip in net profit, the company unveiled a revamped long-term executive remuneration plan aligned with its 2030 strategy.

Ovanti Limited has launched a 1-for-1 entitlement offer to raise approximately AUD 2.293 million at 0.2 cents per share, targeting working capital and offer costs. The offer closes on 1 September 2026 and includes a top-up facility for additional shares.

Guzman y Gomez (ASX: GYG) reported strong FY26 growth with network sales rising 18% and underlying NPAT up 30%, while completing its exit from the US market and announcing a 48 cents fully franked dividend.

Ovanti Limited has announced a complete global exit from the Buy Now Pay Later sector, ceasing all BNPL activities and shifting its focus to its established iSentric business in Southeast Asia, alongside significant cost reductions and imminent legal action against its former US BNPL CEO.

Medical Developments International (ASX:MVP) reported a 9% revenue increase to $42.6 million and a 566% jump in net profit to $0.6 million for FY26, driven by robust growth in its Pain Management segment and expanded paediatric approvals in Europe.

Zip Co Limited (ASX: ZIP) reported a 46% rise in net profit to $116.4 million for FY26, driven by strong US and ANZ market growth and record cash earnings of $268.9 million. The company also announced an orderly wind down of its New Zealand operations to focus on its core markets.

ReNerve Ltd (ASX:RNV) reported an 80% year-on-year revenue increase in Q4 FY26, backed by expanding product lines and a $5 million funding facility. The company is advancing FDA approvals and growing its global distribution footprint, targeting a rapidly expanding $6.19 billion nerve repair biomaterials market.

ImpediMed has secured FDA 510(k) clearance for its SOZO Digital Health Platform to assess sarcopenia risk, marking it as the only FDA-cleared bioimpedance spectroscopy solution for this clinical application. This clearance enables clinicians to non-invasively monitor muscle loss in cancer and chronic disease patients, potentially improving treatment outcomes.